#United States #Leesburg #Biobanking #Creapharm Bioservices #Resonant Clinical Solutions

Resonant Clinical Solutions Expands Its Biobanking Capabilities

Resonant Clinical Solutions, a global leader in clinical solutions for life sciences, has made headlines with its recent acquisition of Creapharm Bioservices, a strategic move that aims to enhance its offerings in biobanking and cryogenic storage. This acquisition is a step toward meeting the rising demand for specialized biobanking services in Europe, enabling Resonant to better support complex clinical programs, particularly those in cell and gene therapy.

Creapharm Bioservices, which operates out of Bailly-Romainvilliers, France, is renowned for its expertise in biobanking and cryogenic storage of biotherapeutics, Advanced Therapy Medicinal Products (ATMPs), and biological samples. The company is equipped to handle various storage needs, including ultra-low temperature storage at -196°C using vapor-phase nitrogen, mechanical freezers, and cold storage that adheres to Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP). This capability is vital, given the trend towards increasingly specialized clinical development programs. A report by IQVIA published in August 2025 revealed that large molecules, including advanced therapies, comprised 46% of clinical trials initiated from phases I to III in 2024, up from 38% five years earlier.

Christophe Berthoux, CEO of Resonant, emphasized the growing necessity for life sciences companies to partner with organizations that possess the specialized infrastructure and international reach crucial for navigating the complex landscape of clinical trials. He stated, “The acquisition of Creapharm Bioservices amplifies our capacity to support clients in developing intricate treatments, especially those related to sensitive cellular therapies, while complementing our existing biobanking, kit preparation, and supply management services. Together, these capabilities drive our strategy to enhance global clinical support.”

Enhancing Specialized Biobanking Capabilities

With Creapharm now part of its Biorepository division, Resonant aims to boost its global presence while offering specialized expertise in cryogenic storage and handling of highly sensitive biological materials. Creapharm's strengths will enrich Resonant’s operations by:

• - Advanced Cryogenic Storage: Handling storage from -196°C to -20°C, ensuring critical temperature controls are maintained throughout the storage process.
• - Traceability Systems: Implementing traceability systems from room temperature to cryogenic conditions, guaranteeing sample integrity.
• - Expertise in Advanced Therapies: Providing specialized knowledge for biotherapies and advanced treatments, essential for today’s evolving clinical landscapes.
• - Regulatory Compliance: Ensuring that operations meet stringent GMP and GDP quality standards.
• - Handling Genetically Modified Organisms (GMOs): Maintaining safety standards for the manipulation of GMOs, ensuring compliance with regulatory frameworks.
• - European Infrastructure Development: Strengthening relationships with clients by expanding operational infrastructure across Europe.

Corey Stone, VP and General Manager of the Biorepository division, hailed the acquisition, stating, “Creapharm Bioservices enhances our ability to support clients handling increasingly sensitive materials and navigating complex clinical programs. We are thrilled to integrate their strong technical expertise and established client relationships into our operations.”

Greg Lavin, CEO of Myonex, recognized that the partnership would allow Myonex to focus on its core competencies while ensuring that Creapharm continues to succeed under Resonant’s leadership. Financial details of the transaction remain undisclosed, but the strategic fit and enhanced capabilities are clear.

About Resonant Clinical Solutions

Resonant Clinical Solutions serves as a global partner specializing in clinical solutions for life sciences organizations, covering the entire clinical supply chain and lifecycle of samples. With over 850 employees across the U.S., U.K., and Europe, the organization has been instrumental in executing over 2,500 clinical trials and managing more than 100 million research assets in storage. The company is committed to providing comprehensive, global clinical supply chain solutions that streamline processes, enabling clients to focus on scientific discovery and patient care. For more information, visit resonantclinical.com.